Adynovate in combination with MYPKFIT®, an FDA-approved application, offers a personalized and interactive prevention treatment option that allows both healthcare professionals (HCPs) and patients to monitor factor VIII levels in real time from their homes by phone
Takeda Pharmaceutical is expanding its portfolio of rare diseases in India by launching Adynovate, an innovative treatment for recombinant factor VIII (rFVIII) with an extended half-life, using established technology (controlled PEGylation) for patients with hemophilia A.
Adynovate in combination with MYPKFIT®, an FDA-approved supplement, offers a personalized and interactive prevention treatment option that allows both healthcare professionals (HCPs) and patients to monitor factor VIII levels in real time from homes over the phone. Alerts are sent to patients who are on prevention when their estimated factor VIII level is low, and remind them when they need to be introduced, which provides excellent preventive coverage.
Commenting on the benefits of preventing patients with hemophilia A, Dr Sandip Arora, head of India’s Department of Health and Patient Services, Takeda said: through prevention as opposed to on-demand therapy. Studies show that the innovative extended half-life, Adynovate, helps patients reduce the dosage and frequency of infusions, thereby improving adherence to treatment by providing personalized preventive coverage. Adynovate has been tested as part of a comprehensive global clinical program that demonstrates favorable safety and efficacy outcomes that provide effective bleeding resolution, better joint health and almost ZERO spontaneous bleeding in the majority. ”
Introduced in three stages with the BAXJECT III system, Adynovate eliminates the need to disinfect the vial, as the vials are already assembled in the system housing. It can be stored at room temperature no higher than 30 ° C (86 ° F) for up to 3 months so as not to exceed the shelf life, which facilitates handling and storage.